Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics)

N/A

Report date: 2024/04/16 10:50:56

Base Information

Drug NameAutologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics)
Drug Alias NameHV-101HV101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionInterleukin-2 replacements
TargetsInterleukin-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTcrcure Biopharma LtdHangzhou Houwu Biomedical Technology Co LtdHervor Therapeutics
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTcrcure Biopharma LtdHangzhou Houwu Biomedical Technology Co Ltd
Inactive CompaniesHervor Therapeutics
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A